Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development
暂无分享，去创建一个
Julia N. Soulakova | Juan I. Young | F. Telischi | X. Liu | M. Giovannini | Jeremie Vitte | Marisa A. Fuse | S. Plati | C. Dinh | O. Bracho | R. Mittal | Rulong Z. Shen | A. Copik | Long-Sheng Chang | M. Franco | C. Fernández-Valle | H. Morrison | Joanna M. Kirkpatrick | T. Mindos | Jie Huang | Annemarie Carlstedt | Konstantin Brnjoš | Jackson D Nagamoto | A. Petrilli | D. Yan | C. Fernández‐Valle | Jackson Nagamoto | C. Fernandez-Valle | Alejandra M Petrilli